Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day at $26.31. Traded volume was 7,684,553 million shares in the last session and the average volume of the stock remained 1.10 million shares. The beta of the stock remained 2.60. Arrowhead Research Corp (NASDAQ:ARWR) insider ownership is 1.20%.

Dara Biosciences Inc (NASDAQ:DARA) signed a Medicare Part D prescription drug reimbursement agreement with Wellcare Health Plans Inc. (WCG), providing its Soltamox breast-cancer drug with access to the managed-care company’s extensive network. DARA Biosciences Inc (NASDAQ:DARA) rose 8.62 percent to $3.15 yesterday on volume of 2.97million shares. The intra-day range of the stock was $3.15 to $3.55. DARA Biosciences Inc (NASDAQ:DARA) has a market capitalization of $26.40 million.

Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 26th Annual ROTH Conference being held on March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 11, 2014 at 2:00 p.m. (Pacific Time). Synthetic Biologics Inc (NYSEMKT:SYN)’s stock on Mar 5 , 2014 reported an increase of 5.07% to the closing price of $2.90. Its fifty two weeks range is $ 0.95 -$ 3.05. The total market capitalization recorded $168.20 million. The overall volume in the last trading session was 2,496,280 million shares. In its share capital, Synthetic Biologics Inc (NYSEMKT:SYN) has 44.65 million outstanding shares.

Oncothyreon Inc. (USA) (NASDAQ:ONTY) presented at the Cowen and Company 34th Annual Health Care Conference in Boston. On Wednesday, shares of Oncothyreon Inc (USA) (NASDAQ:ONTY) advanced 9.91% to close the day at $3.55. Company monthly performance is recorded as 67.45%. Oncothyreon Inc (USA) (NASDAQ:ONTY) quarterly revenue growth is 80.20%.